Physician profile
Greg E Sharon
NPI 1619950250
$10,613.41
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,042 · 2020: $2,074 · 2021: $2,262 · 2022: $2,430 · 2023: $1,701 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $1,609.87 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,322.06 | 2019-2023 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,175.71 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $708.53 | 2020-2023 | Cuvitru, Hyqvia, Takhzyro |
| Csl Behring | $655.30 | 2019-2024 | Haegarda, Kcentra, Hizentra |
| Abbvie INC. | $457.12 | 2021-2023 | Ubrelvy, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $419.36 | 2019-2023 | Dupixent |
| Genentech USA, INC. | $404.46 | 2019-2023 | Xolair |
| Covis Pharma Gmbh | $380.18 | 2019-2022 | |
| Shire North American Group INC | $375.91 | 2019 | |
| Grifols USA, LLC | $337.58 | 2019-2022 | |
| Pharming Healthcare, INC. | $286.74 | 2019-2023 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.22 | 2020-2023 | Spiriva Respimat |
| Genzyme Corporation | $262.74 | 2021-2023 | |
| Amgen INC. | $247.60 | 2021-2023 | Tezspire |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $246.40 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $210.08 | 2021-2022 | |
| Pfizer INC. | $158.01 | 2019-2024 | |
| Bio Products Laboratory USA, INC. | $153.81 | 2021-2023 | Gammaplex, Coagadex |
| Novartis Pharmaceuticals Corporation | $144.48 | 2019-2024 | |
| Octapharma USA, INC. | $117.59 | 2019-2021 | |
| Blueprint Medicines Corporation | $109.05 | 2023 | Ayvakit |
| Kaleo, INC. | $99.27 | 2019-2023 | Auvi-Q |
| Kedrion Biopharma INC. | $72.13 | 2019 | |
| Alk-Abello, INC | $67.21 | 2019-2023 | Standardized Mite D. Farinae, Timothy, Standardized, Histamine Positive |
| Qol Medical, LLC | $56.91 | 2019 | |
| Aimmune Therapeutics, INC. | $54.33 | 2022 | |
| Biocryst US Sales Co., LLC | $52.81 | 2021-2023 | Orladeyo |
| Hospira, INC. | $25.04 | 2022 | |
| Leo Pharma INC. | $23.63 | 2022 | |
| Eyevance Pharmaceuticals LLC | $23.30 | 2021 | |
| Incyte Corporation | $21.17 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $18.75 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.53 | 2022 | |
| Phadia US INC. | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Sharon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.